Effect of eicosapentaenoic acid in asthma

C. M. KIRSCH, D. G. PAYAN, M. Y S WONG, J. G. DOHLMAN, V. A. BLAKE, Michelle Petri, J. OFFENBERGER, E. J. GOETZL, W. M. GOLD

Research output: Contribution to journalArticle

Abstract

The role of arachidonic acid metabolites in the pathogenesis of airway inflammation and clinical asthma is currently unknown. The addition of eicosapentaenoic acid (EPA) to the diet of humans has been shown to generate metabolites that are less potent than their arachidonic acid counterparts. The substitution of EPA for arachidonic acid metabolites in patients might cause a decrease in airway inflammation and an improvement in clinical asthma. We studied the effect of addition of EPA to the diet of twelve asthmatic patients. Standard clinical evaluations and pulmonary function tests were done on weeks 0, 3, 6, 10, 12 and 14. Patients ingested either low‐dose EPA (0.1 g/day) or high‐dose EPA (4.0 g/day) from weeks 6–14 (total of 8 weeks). There was no difference in clinical status or pulmonary function between groups at the start of the study. There was no change in clinical status or pulmonary function between or within groups at the end of 8 weeks of EPA ingestion.

Original languageEnglish (US)
Pages (from-to)177-187
Number of pages11
JournalClinical & Experimental Allergy
Volume18
Issue number2
DOIs
StatePublished - 1988

Fingerprint

Eicosapentaenoic Acid
Asthma
Arachidonic Acid
Diet
Inflammation
Lung
Respiratory Function Tests
Eating

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

KIRSCH, C. M., PAYAN, D. G., WONG, M. Y. S., DOHLMAN, J. G., BLAKE, V. A., Petri, M., ... GOLD, W. M. (1988). Effect of eicosapentaenoic acid in asthma. Clinical & Experimental Allergy, 18(2), 177-187. https://doi.org/10.1111/j.1365-2222.1988.tb02857.x

Effect of eicosapentaenoic acid in asthma. / KIRSCH, C. M.; PAYAN, D. G.; WONG, M. Y S; DOHLMAN, J. G.; BLAKE, V. A.; Petri, Michelle; OFFENBERGER, J.; GOETZL, E. J.; GOLD, W. M.

In: Clinical & Experimental Allergy, Vol. 18, No. 2, 1988, p. 177-187.

Research output: Contribution to journalArticle

KIRSCH, CM, PAYAN, DG, WONG, MYS, DOHLMAN, JG, BLAKE, VA, Petri, M, OFFENBERGER, J, GOETZL, EJ & GOLD, WM 1988, 'Effect of eicosapentaenoic acid in asthma', Clinical & Experimental Allergy, vol. 18, no. 2, pp. 177-187. https://doi.org/10.1111/j.1365-2222.1988.tb02857.x
KIRSCH, C. M. ; PAYAN, D. G. ; WONG, M. Y S ; DOHLMAN, J. G. ; BLAKE, V. A. ; Petri, Michelle ; OFFENBERGER, J. ; GOETZL, E. J. ; GOLD, W. M. / Effect of eicosapentaenoic acid in asthma. In: Clinical & Experimental Allergy. 1988 ; Vol. 18, No. 2. pp. 177-187.
@article{8ed111b8ddd7414c86674f99a15be3d2,
title = "Effect of eicosapentaenoic acid in asthma",
abstract = "The role of arachidonic acid metabolites in the pathogenesis of airway inflammation and clinical asthma is currently unknown. The addition of eicosapentaenoic acid (EPA) to the diet of humans has been shown to generate metabolites that are less potent than their arachidonic acid counterparts. The substitution of EPA for arachidonic acid metabolites in patients might cause a decrease in airway inflammation and an improvement in clinical asthma. We studied the effect of addition of EPA to the diet of twelve asthmatic patients. Standard clinical evaluations and pulmonary function tests were done on weeks 0, 3, 6, 10, 12 and 14. Patients ingested either low‐dose EPA (0.1 g/day) or high‐dose EPA (4.0 g/day) from weeks 6–14 (total of 8 weeks). There was no difference in clinical status or pulmonary function between groups at the start of the study. There was no change in clinical status or pulmonary function between or within groups at the end of 8 weeks of EPA ingestion.",
author = "KIRSCH, {C. M.} and PAYAN, {D. G.} and WONG, {M. Y S} and DOHLMAN, {J. G.} and BLAKE, {V. A.} and Michelle Petri and J. OFFENBERGER and GOETZL, {E. J.} and GOLD, {W. M.}",
year = "1988",
doi = "10.1111/j.1365-2222.1988.tb02857.x",
language = "English (US)",
volume = "18",
pages = "177--187",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Effect of eicosapentaenoic acid in asthma

AU - KIRSCH, C. M.

AU - PAYAN, D. G.

AU - WONG, M. Y S

AU - DOHLMAN, J. G.

AU - BLAKE, V. A.

AU - Petri, Michelle

AU - OFFENBERGER, J.

AU - GOETZL, E. J.

AU - GOLD, W. M.

PY - 1988

Y1 - 1988

N2 - The role of arachidonic acid metabolites in the pathogenesis of airway inflammation and clinical asthma is currently unknown. The addition of eicosapentaenoic acid (EPA) to the diet of humans has been shown to generate metabolites that are less potent than their arachidonic acid counterparts. The substitution of EPA for arachidonic acid metabolites in patients might cause a decrease in airway inflammation and an improvement in clinical asthma. We studied the effect of addition of EPA to the diet of twelve asthmatic patients. Standard clinical evaluations and pulmonary function tests were done on weeks 0, 3, 6, 10, 12 and 14. Patients ingested either low‐dose EPA (0.1 g/day) or high‐dose EPA (4.0 g/day) from weeks 6–14 (total of 8 weeks). There was no difference in clinical status or pulmonary function between groups at the start of the study. There was no change in clinical status or pulmonary function between or within groups at the end of 8 weeks of EPA ingestion.

AB - The role of arachidonic acid metabolites in the pathogenesis of airway inflammation and clinical asthma is currently unknown. The addition of eicosapentaenoic acid (EPA) to the diet of humans has been shown to generate metabolites that are less potent than their arachidonic acid counterparts. The substitution of EPA for arachidonic acid metabolites in patients might cause a decrease in airway inflammation and an improvement in clinical asthma. We studied the effect of addition of EPA to the diet of twelve asthmatic patients. Standard clinical evaluations and pulmonary function tests were done on weeks 0, 3, 6, 10, 12 and 14. Patients ingested either low‐dose EPA (0.1 g/day) or high‐dose EPA (4.0 g/day) from weeks 6–14 (total of 8 weeks). There was no difference in clinical status or pulmonary function between groups at the start of the study. There was no change in clinical status or pulmonary function between or within groups at the end of 8 weeks of EPA ingestion.

UR - http://www.scopus.com/inward/record.url?scp=85004830111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004830111&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2222.1988.tb02857.x

DO - 10.1111/j.1365-2222.1988.tb02857.x

M3 - Article

VL - 18

SP - 177

EP - 187

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 2

ER -